| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 6. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | atomoxetine (Strattera®) |
| Formulation | 4mg/ml oral solution |
| Reference number | 2816 |
| Indication | Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme |
| Company | Eli Lilly & Co Ltd |
| BNF chapter | Central nervous system |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 19/06/2015 |